Allogene Therapeutics Files 8-K
Ticker: ALLO · Form: 8-K · Filed: Aug 1, 2025 · CIK: 1737287
| Field | Detail |
|---|---|
| Company | Allogene Therapeutics, Inc. (ALLO) |
| Form Type | 8-K |
| Filed Date | Aug 1, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: ALLO
TL;DR
ALLO filed an 8-K, but it's light on details. Need more info.
AI Summary
Allogene Therapeutics, Inc. filed an 8-K on August 1, 2025, reporting other events. The filing does not contain specific details about the nature of these events, dollar amounts, or new agreements.
Why It Matters
This filing indicates a corporate event has occurred for Allogene Therapeutics, but the lack of detail means investors need to seek further information to understand its implications.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not disclose any immediate financial or operational risks.
Key Players & Entities
- Allogene Therapeutics, Inc. (company) — Registrant
- August 1, 2025 (date) — Date of earliest event reported
FAQ
What specific 'Other Events' are being reported by Allogene Therapeutics, Inc. in this 8-K filing?
The filing does not specify the nature of the 'Other Events' beyond listing it as the item information.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on August 1, 2025.
What is the principal executive office address for Allogene Therapeutics, Inc.?
The address is 210 East Grand Avenue, South San Francisco, California 94080.
What is the telephone number for Allogene Therapeutics, Inc.?
The telephone number is (650) 457-2700.
Under which section of the Securities Exchange Act of 1934 is this 8-K report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 1, 2025 regarding Allogene Therapeutics, Inc. (ALLO).